Advice
following a full submission:
telaprevir (Incivo®) is accepted for use within NHS Scotland.
Indication under review: in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis) who are treatment-naïve.
In the pivotal phase III randomised study, addition of telaprevir to current standard therapy in treatment-naïve patients with genotype 1 chronic hepatitis C virus, significantly increased the proportion of patients who achieved a sustained virologic response, even in patients treated for a shorter overall duration using response-guided therapy.
Download detailed advice136KB (PDF)
Medicine details
- Medicine name:
- telaprevir (Incivo) Naive
- SMC ID:
- 743/11
- Indication:
- In combination with peginterferon alfa and ribavirin (PR), for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis): who are treatment naive
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 December 2011